RARA and acute myeloid leukemia: FTO is significantly upregulated in AMLs with t(11q23)/MLL rearrangements, t(15;17)/PML-RARA, FLT3-ITD, and/or NPM1 mutations, and exerts an oncogenic role in AML by post-transcriptionally downregulating expression of critical transcripts such as ASB2 and RARA through m6A demethylation activity (Li et al. 2017b).